On this page
Back pain is the commonest reason anyone seeks any treatment anywhere, which makes it the most commercially attractive indication in regenerative medicine and one of the hardest to study honestly. Degenerative disc disease and stem cell therapy has randomised evidence, including a trial that did not find what its sponsors hoped.
What disc degeneration is
Intervertebral discs sit between the vertebrae, each with a tough outer ring and a gel-like centre that loses water content with age. As it dehydrates, disc height falls, the outer ring develops fissures, and load transfers to the small facet joints behind.
This happens to almost everyone. Imaging studies of people with no back pain at all show disc degeneration in a large proportion by middle age, rising steeply with each decade.
Which is the central difficulty: a degenerate disc on your scan may or may not be the source of your pain, and the scan cannot tell you which.
“Degenerative disc disease” is arguably a poor name for a near-universal ageing process. It is a description of an appearance, not automatically a diagnosis.
Why attribution is the hard part
Back pain has many possible sources in a small space — disc, facet joints, sacroiliac joint, muscle, nerve root, and central sensitisation where the nervous system amplifies signals regardless of what is happening in the tissue.
Discography, which pressurises a disc to see whether it reproduces the pain, exists to address this and is itself contested, partly because it may accelerate degeneration of the disc it tests.
A treatment aimed at the disc will do nothing for pain coming from somewhere else, and there is no reliable way to be certain in advance.
What standard care offers
Exercise therapy and graded activity, which have the best evidence and are the least used. Staying active beats rest across the literature.
Physiotherapy, and for chronic pain increasingly a multidisciplinary approach addressing sleep, mood and activity alongside the back itself.
Simple analgesia. Injections for specific identified sources. Surgery — fusion or disc replacement — has more contested evidence for degenerative pain than for nerve compression, and outcomes are variable.
That mixed surgical picture is part of why regenerative alternatives attract interest here.
Why cells are proposed for the disc
The disc has very poor blood supply, so cells within it live in a hostile low-oxygen, low-nutrient, acidic environment. That is both the reason discs heal badly and the reason injected cells may not survive long.
The proposed mechanisms are supporting the remaining disc cells, modulating inflammation, and slowing the progressive loss of matrix.
A frank limitation: the environment that damaged the native cells is the same environment any injected cells arrive in.
What the trials found
A randomised controlled trial examined disc repair using allogeneic bone marrow cells — Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial.
A 2024 study assessed allogeneic bone marrow-derived MSC therapy in chronic low back pain — Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain — and a 2025 trial examined allogeneic mesenchymal precursor cells with and without hyaluronic acid — Efficacy and safety of allogeneic mesenchymal precursor cells with and without hyaluronic acid.
A 2024 systematic review assessed intradiscal regenerative therapies for long-term relief — Effectiveness of Intradiscal Regenerative Medicine Therapies for Long-Term Relief of Chronic Low Back Pain — and autologous approaches have been reviewed separately — Autogenic mesenchymal stem cells for intervertebral disc regeneration.
Reading the results honestly
This is one of the few indications where a well-conducted trial has been run at scale by a commercial sponsor — and where the results did not clearly support the product.
That is worth more than it sounds. A field where negative results get published is a field you can trust more, not less.
The pattern across these studies is modest effects, considerable variability, and real difficulty separating treatment from the natural fluctuation of chronic back pain, which improves and worsens in cycles regardless of intervention.
Who might be considered
Chronic discogenic pain with imaging that matches the symptoms, conservative treatment already exhausted, and a disc that has not collapsed entirely — there has to be something left to support.
Nerve compression causing leg pain, weakness or bladder symptoms is a different problem needing different management, sometimes urgently.
Pain that has become widespread, with poor sleep and low mood, is often better addressed through a pain programme than through anything injected — see what the evidence levels mean.
Risks specific to the disc
Discitis — infection within the disc — is uncommon and serious, difficult to treat because of the same poor blood supply that causes the original problem.
The injection itself can accelerate degeneration of a disc that was borderline, which is the concern raised about discography.
General risks apply as elsewhere — see adverse events and MSC therapy.
There is a practical risk too, particular to back pain: chronic pain fluctuates, and a treatment given during a bad spell will often be followed by improvement that had nothing to do with it. That makes personal testimony in this condition especially unreliable, including your own.
Questions to ask
The attribution problem should shape the conversation.
- How confident is anyone that my pain comes from the disc rather than elsewhere?
- What imaging supports that, and does it match my symptoms?
- Which trial supports this preparation, at this dose, in the disc?
- Have I completed a proper course of exercise-based treatment?
- What happens if the pain does not change?
See osteoarthritis for a joint where attribution is easier and evidence is stronger.
The back pain trials described here are routinely quoted for a condition they never studied — fibromyalgia and chronic pain sets out why they do not transfer.
Frequently asked questions
Is my disc the cause of my pain?
Possibly not. Disc degeneration appears on scans of many people with no pain at all, and no imaging can confirm the disc is the source.
Is there randomised evidence?
Yes, several trials including commercially sponsored ones. Results are mixed, and at least one did not clearly support the product being tested.
Why would cells survive in a disc?
That is a genuine concern. The disc has poor blood supply and a hostile environment — the same conditions that damaged the original cells.
Is it better than fusion surgery?
No trial has compared them directly. Surgical evidence for degenerative pain is itself more contested than for nerve compression.
What should I try first?
Exercise therapy and graded activity, which have the best evidence in back pain and are consistently underused.
What are the specific risks?
Discitis, which is uncommon and serious, and the possibility that injecting a borderline disc accelerates its degeneration.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.